ARD1 Inhibitors
The chemical class of ARD1 inhibitors comprises a variety of compounds that indirectly influence the activity of ARD1. These inhibitors work through diverse mechanisms, reflecting the intricate nature of cellular signaling and the complexity of interactions within protein networks. Unlike direct inhibitors, these chemicals modulate different signaling pathways and cellular processes that are associated with or influence the regulation of ARD1, leading to its reduced activity.
The compounds in this class target a range of molecules and pathways. For instance, inhibitors like Gefitinib and Erlotinib block EGFR, impacting downstream signaling pathways that can modulate ARD1 activity. PKA inhibitors such as H-89 and multi-kinase inhibitors like Sunitinib and Sorafenib demonstrate the broad spectrum of targets within this chemical class, each influencing different aspects of cellular signaling that intersect with ARD1 regulation. The actions of these inhibitors highlight the interconnectedness of cellular pathways and the potential for indirect modulation of protein activity.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor. By blocking EGFR, it downregulates the downstream signaling that could potentially modulate ARD1 activity, thereby acting as an indirect inhibitor of ARD1. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $92.00 $182.00 | 71 | |
As a PKA inhibitor, H-89 downregulates cAMP-dependent protein kinase A, which can intersect with pathways influencing ARD1 activity, thus potentially reducing ARD1's function indirectly. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $256.00 | 18 | |
Tamoxifen acts as an estrogen receptor modulator. This modulation can influence various signaling pathways that intersect with those regulating ARD1, potentially leading to reduced ARD1 activity. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
This compound is a GSK-3β inhibitor. By inhibiting GSK-3β, it affects the Wnt signaling pathway, potentially leading to downstream effects that could reduce ARD1 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
As a MEK inhibitor, PD98059 impacts the MAPK/ERK pathway. Altering this pathway can indirectly lead to a reduction in ARD1 activity through various cellular mechanisms. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits the JNK pathway. By modulating this pathway, it could indirectly influence ARD1 activity, potentially leading to its inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor, affecting the PI3K/AKT pathway. This can lead to indirect effects on ARD1 activity by modulating interconnected cellular processes. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib targets multiple receptor tyrosine kinases. Its broad-spectrum activity may intersect with pathways influencing ARD1, potentially acting as an indirect inhibitor. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor, known to affect several pathways including those that might intersect with ARD1, potentially leading to its inhibition. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
This compound is an EGFR inhibitor, similar to Gefitinib, and can downregulate pathways potentially influencing ARD1, acting as an indirect inhibitor. | ||||||